| Dose Level | ||
---|---|---|---|
 | 300 mg/m2 | 400 mg/m2 | 500 mg/m2 |
No. of patients | 3 | 3 | 23 |
Age (years) | Â | Â | Â |
   Mean | 68 | 50 | 58 |
   Range | 63–75 | 42–62 | 40–75 |
Sex | Â | Â | Â |
   Male | 3 | 1 | 17 |
   Female | 0 | 2 | 6 |
Karnofsky Performance Status | Â | Â | Â |
   100% | 2 | 1 | 9 |
   90% | 0 | 1 | 7 |
   80% | 1 | 1 | 7 |
Clinical stage | Â | Â | Â |
   cT2cN3 | 0 | 0 | 2 |
   cT3cN2 | 2 | 0 | 1 |
   cT3cN3 | 0 | 0 | 6 |
   cT4 cN0 | 0 | 0 | 6 |
   cT4 cN2 | 0 | 2 | 5 |
   cT4 cN3 | 1 | 1 | 3 |
Histology | Â | Â | Â |
   Adenocarcinoma | 0 | 2 | 6 |
   Squamous Carcinoma | 1 | 1 | 15 |
   Adenosquamous Carcinoma | 1 | 0 | 1 |
   Large-Cell Carcinoma | 1 | 0 | 1 |